Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Editorial

Wearable cardiac monitors: Where do we stand?

Jakub Sroubek, MD, PhD
Cleveland Clinic Journal of Medicine January 2024, 91 (1) 31-32; DOI: https://doi.org/10.3949/ccjm.91a.23081
Jakub Sroubek
Department of Cardiovascular Medicine and Division of Cardiac Pacing and Electrophysiology, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Find this author on Cleveland Clinic
  • Article
  • Info & Metrics
  • PDF
Loading

Oh, how time flies! When I started my postgraduate training a decade ago, evaluation of (most) patients with palpitations was simple: history, physical examination, and a 48-hour Holter monitor. In those days, affordable consumer-grade cardiac monitors were based solely on photoplethysmography (PPG, akin to pulse oximetry), which in its early form rarely offered actionable diagnostic information for an electrophysiologist. Instead, a clinical-grade Holter monitor was needed. Holter monitors and the related event monitors were conceptualized in the late 1940s1 and commercialized in the early 1960s, but their fundamental design, management, and interpretation has changed very little over time. While not always practical for the patient, the devices represented a tried-and-true diagnostic tool for most clinicians.

See related article, page 23

Over the past decade, marked improvement in both the quality and affordability of consumer-grade wearable monitors has changed the game completely—especially after many products acquired the ability to record single-lead electrocardiogram (ECG) tracings. This is most apparent in the outpatient electrophysiology clinic, where patients routinely hand me their phones and ask me to scroll through their ECG logs. I do this gladly, and not just to humor them. The home ECG data are incredibly helpful! Countless times, these tracings have directly affected patient management.

While Holter and event monitors continue to play a major role in patient care, the consumer-grade cardiac monitors are becoming just as important, and their value, reliability, and ubiquity will only grow. Regardless of one’s technological savvy, any practicing clinician should be familiar with the most frequently used wear able cardiac monitors and, importantly, with the clinical evidence that supports or challenges their utility.

In this issue of the Journal, Mohamoud et al2 provide a helpful and succinct review of the most up-to-date clinical information behind consumer-grade wearable monitors. They make it clear that the bulk of research efforts so far have focused on proving the utility of PPG-based devices as population-wide screening tools for atrial fibrillation. The 2 largest studies—the Apple Heart Study3 and the Fitbit Heart Study4—together enrolled almost 1 million patients and proved that wearable monitors do indeed perform well as screening tools for atrial fibrillation.

While such information is crucial for future research efforts, it has little direct impact on the day-to-day practice of most clinicians. Indeed, Mohamoud et al2 show that some nuanced but clinically crucial questions have barely been addressed. From the vantage point of a clinical electrophysiologist, I am interested in consideration of 3 dilemmas, discussed below.

DO WEARABLE CARDIAC MONITORS TRANSLATE TO STROKE PREVENTION?

The idea is simple: patients self-detect incidental atrial fibrillation on wearable cardiac monitors. After confirming the diagnosis, a physician prescribes therapeutic anticoagulation to appropriate patients (eg, after risk-stratification using the CHA2DS2-VASc5 model or similar) and prevents cardioembolic events.

But we know that things are rarely so simple. For example, when patients with permanent pacemakers experience asymptomatic episodes of atrial fibrillation, their risk of stroke is indeed higher than that of the general population, but it is considerably lower than that predicted by the CHA2DS2-VASc model.6 It is easy to imagine that if we extend the atrial fibrillation screening process to an even healthier population (ie, anyone in the general public wearing a consumer-grade monitor), the applicability of existing risk-stratification paradigms may decline even more.

In practical terms, should we start therapeutic anticoagulation in every 66-year-old man with hypertension (CHA2DS2-VASc score of 2) who walks into our office and shows us an Apple watch tracing with 15 minutes of atrial fibrillation? Additional studies are needed to address this question.

WHAT IS THE ROLE OF WEARABLE CARDIAC MONITORS FOR OTHER INDICATIONS?

As shown by Mohamoud and colleagues, most evidence for wearable monitors circles around de novo screening for atrial fibrillation. Relatively less is known about using these devices to manage patients with known atrial fibrillation. In our practice, we often ask patients to send us KardiaMobile ECG tracings once a week (or whenever the patient is symptomatic) for 3 months after undergoing catheter ablation. This approach makes intuitive sense and, in our experience, has been very effective in identifying early recurrences of atrial fibrillation. But it has never been formally studied.

The utility of cardiac wearables in the diagnosis and management of suspected short-duration arrhythmias is also unknown. Patients with symptoms caused by cardiac ectopy are often managed based on the absolute burden of premature beats. Will wearable devices help with that? What about patients with syncope? Will PPG-based wearable devices ever be able to provide sufficiently granular diagnostic information, or will clinical-grade ECG Holter devices always be necessary?

CAN WE STREAMLINE CLINICAL INTERPRETATION?

As noted, in our electrophysiology practice, established patients with arrhythmias occasionally ask to have their home device ECG tracings reviewed by a physician. Patients who require frequent ECG monitoring may also subscribe to a service that enables them to send their KardiaMobile ECG tracings directly to our device clinic, where a team of nurses and technicians can quickly review the information. This helps ensure prompt diagnosis of arrhythmias (if present), and it improves patient satisfaction and provides reassurance. In some cases, this ECG review precludes an unnecessary office or emergency room visit. Today, the volume of such information exchange is manageable, but as more patients purchase home monitors, the availability and affordability of review services may become limited unless systemic change is implemented.

The problem of scaling is even more evident when we consider population-wide screening using consumer-grade cardiac monitors. Most wearable devices provide automatic detection of atrial fibrillation, but its clinical verification remains manual. Even if we accept the high precision of the automated diagnosis of atrial fibrillation (a positive predictive value near 98% in the FitBit Heart Study4), most clinicians would be reluctant to treat new patients based only on what their home monitor app reports. Instead, physicians typically review the primary device data manually or reassess the patient with a Holter monitor or both before moving to treatment. In some cases, this may result in a specialty (cardiology) or subspecialty (electrophysiology) referral. Like the subscription services we provide in our practice, this process may be sustainable now, but increased numbers of self-screened individuals might require a more streamlined approach. What this would look like remains to be seen, but the possibilities include workforce extension (more ECG technicians in hospital and industry) and technology so precise that manual confirmation will be unnecessary.

CLOSING THOUGHTS

Technological advances have enabled us to reimagine the diagnosis and management of cardiac arrhythmias, especially atrial fibrillation. Judicious application of these enhanced tools will require continued analysis of their potential, as well as how to manage the data they generate.

DISCLOSURES

The author reports no relevant financial relationships which, in the context of his contributions, could be perceived as a potential conflict of interest.

  • Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Holter NJ,
    2. Holter NJ
    . Remote recording of physiological data by radio. Rocky Mt Med J 1949; 46(9):747–751. pmid:18137532
    OpenUrlPubMed
  2. ↵
    1. Mohamoud A,
    2. Jensen J,
    3. Buda KG
    . Consumer-grade wearable cardiac monitors: what do they do well, and what needs work. Cleve Clin J Med 2024; 91:23–29. doi:10.3949/ccjm.91a.23030
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Perez MV,
    2. Mahaffey KW,
    3. Hedlin H, et al
    . Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med 2019; 381(20):1909–1917. doi:10.1056/NEJMoa1901183
    OpenUrlCrossRefPubMed
  4. ↵
    1. Lubitz SA,
    2. Faranesh AZ,
    3. Selvaggi C, et al
    . Detection of atrial fibrillation in a large population using wearable devices: the Fitbit Heart Study. Circulation 2022; 146(19):1415–1424. doi:10.1161/CIRCULATIONAHA.122.060291
    OpenUrlCrossRef
  5. ↵
    1. Lip GYH,
    2. Nieuwlaat R,
    3. Pisters R,
    4. Lane DA,
    5. Crijns HJGM
    . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137(2):263–272.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Healey JS,
    2. Connolly SJ,
    3. Gold MR, et al
    . Subclinical atrial fibrillation and the risk of stroke [published correction appears in N Engl J Med 2016; 374(10):998]. N Engl J Med 2012; 366(2):120–129. doi:10.1056/NEJMoa1105575
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 91 (1)
Cleveland Clinic Journal of Medicine
Vol. 91, Issue 1
1 Jan 2024
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Wearable cardiac monitors: Where do we stand?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Wearable cardiac monitors: Where do we stand?
Jakub Sroubek
Cleveland Clinic Journal of Medicine Jan 2024, 91 (1) 31-32; DOI: 10.3949/ccjm.91a.23081

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Wearable cardiac monitors: Where do we stand?
Jakub Sroubek
Cleveland Clinic Journal of Medicine Jan 2024, 91 (1) 31-32; DOI: 10.3949/ccjm.91a.23081
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • DO WEARABLE CARDIAC MONITORS TRANSLATE TO STROKE PREVENTION?
    • WHAT IS THE ROLE OF WEARABLE CARDIAC MONITORS FOR OTHER INDICATIONS?
    • CAN WE STREAMLINE CLINICAL INTERPRETATION?
    • CLOSING THOUGHTS
    • DISCLOSURES
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • Consumer-grade wearable cardiac monitors: What they do well, and what needs work
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The beat goes on: Highlights from the new American and European A-fib guidelines
  • Subclinical hypothyroidism: What’s in a name?
  • Heart to heart: Progress in cardiovascular disease prevention for people living with HIV
Show more Editorial

Similar Articles

Subjects

  • Cardiology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire